Literature DB >> 6580941

Male reproductive capacity may recover following drug treatment with the L-10 protocol for acute lymphocytic leukemia.

D P Evenson, Z Arlin, S Welt, M L Claps, M R Melamed.   

Abstract

Six men with acute lymphocytic leukemia (ALL) were studied prospectively to assess the effect of treatment with the L-10 protocol on reproductive capacity. Before therapy three men had fathered children (two, two children; one, three children); the others were sexually mature although no fertility studies had been done prior to or during their treatment. Each patient had a minimum of 3 1/2 years of continuous chemotherapy as part of this study. Semen analysis was done 10 to 52 months (median, 31.5 months) after completion of therapy. One patient had lower than normal sperm concentration but near normal total sperm count and normal motility; the others had a normal sperm concentration and motility. Sperm nuclei were isolated from each sample and analyzed by flow cytometry for resistance to DNA denaturation in situ; all samples had relatively high resistance to denaturation, consistent with a normal, fertile reproductive status. After completion of therapy, one patient fathered a normal child, and a second patient fathered one child with multiple congenital malformations followed by a second child who was normal.

Entities:  

Mesh:

Year:  1984        PMID: 6580941     DOI: 10.1002/1097-0142(19840101)53:1<30::aid-cncr2820530108>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Cancer, chemotherapy, and fertility.

Authors:  J Waxman
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

Review 2.  [Radiation reactions in the gonads: importance in patient counseling].

Authors:  T Herrmann
Journal:  Strahlenther Onkol       Date:  1997-10       Impact factor: 3.621

Review 3.  Male gonadal toxicity.

Authors:  Marvin L Meistrich
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

4.  Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.

Authors:  A Ravaud; N B Bui; J M Coindre; P Lagarde; P Tramond; F Bonichon; E Stöckle; G Kantor; M Trojani; J Chauvergne
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.